Contact Us
Drug Search Results
More Filters [+]

Mercaptamine

Alternative Names: mercaptamine, cysteamine, cystagon, cysteamine hydrochloride, rp-103, rp 103, rp103, procysbi, cystaran, cystadrops
Latest Update: 2024-08-28
Latest Update Note: News Article

Product Description

Mercaptamine (cysteamine) bitartrate is used for metabolic conditions (the management of nephropathic cystinosis) and is available in a 50mg or 150mg tablet. (Sourced from: https://www.tga.gov.au/alert/mercaptamine-cysteamine-and-mercaptopurine)

Mechanisms of Action: Autophagy Activator,TG2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Chile | Colombia | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | United Arab Emirates | United Kingdom | United States

Approved Indications: Cystinosis | Cystinosis | Cystinosis | Cystinosis

Known Adverse Events: Eye Pain | Headache | Pain Unspecified | Pruritus | Ocular Discomfort | Abdominal Pain | Dizziness | Anorexia | Diarrhea | Enteritis | Gastroenteritis

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mercaptamine

Countries in Clinic: Australia, Belgium, Canada, Colombia, Croatia, France, Germany, Hungary, India, Ireland, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Spain, United Kingdom, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: COVID-19|Cystinosis|Influenza, Human|Pneumonia

Phase 2: Cystic Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
REMAP-CAP

P3

Recruiting

COVID-19|Pneumonia|Influenza, Human

2026-02-01

SCOB2

P3

Completed

Cystinosis

2022-12-23

68%
jRCT2021200029

P3

Not yet recruiting

Cystinosis

2021-12-31

2015-004986-99

P2

Active, not recruiting

Cystic Fibrosis

2017-07-11

Recent News Events

Date

Type

Title

08/28/2024

News Article

 LIAN Group Expands Healthcare Platform with Strategic Acquisition of Scientis, #1 Dermatologist-Recommended Solution for Hyperpigmentation

08/27/2024

News Article

 LIAN Group Expands Healthcare Platform with Strategic Acquisition of Scientis, #1 Dermatologist-Recommended Solution for Hyperpigmentation

04/10/2024

News Article

 Cyspera® Celebrates Triple Triumph in Prestigious Beauty Awards Across US and Asia Regions for Breakthroughs in Hyperpigmentation

10/05/2023

News Article

 Nephropathic Cystinosis Treatment Market Size, Share and Forecast 2031

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions